2-[[2-(4-methoxyphenoxy)acetyl]amino]benzoic Acid | 69764-06-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[[2-(4-methoxyphenoxy)acetyl]amino]benzoic Acid
• CAS: 69764-06-3
• 化学式: C₁₆H₁₅NO₅
• 分子量: 301.299
• InChiKey: JHCUZGSREIUIPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[[2-(4-methoxyphenoxy)acetyl]amino]benzoic Acid 在 氯化亚砜 、 三溴化硼 、 苯酚 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 N¹-(7-(2-(dimethylamino)ethoxy)benzofuro[3,2-b]quinolin-11-yl)butane-1,4-diamine
  参考文献：
  名称：

  一种甲基苯并呋喃喹啉类的生物探针及其制备 方法和应用

  摘要：

  本发明同时公开了苯并呋喃喹啉生物探针及其制备方法和在检测G-四链体结构和在白叶藤碱与G-四链体作用机制中的用途，该类生物探针具有很强的荧光强度和很好的荧光性能，可用于特异性检测G-四链体结构以及研究白叶藤碱衍生物与G-四链体的作用机制。研究白叶藤碱衍生物在体内是作用于端粒G-四链体还是启动子区域的C-MYC G-四链体更或者是其他G-四链体结构，检测方法具有操作简便，快捷，选择性好，可视化明显的优点，克服了其他检测方法体内检测无法进行以及价格昂贵，设备要求高，技术操作相对复杂等缺点。

  公开号：

  CN103666452B
• 作为产物：
  描述：

  对甲氧基苯氧乙酸 在 sodium hydroxide 、 氯化亚砜 作用下， 生成 2-[[2-(4-methoxyphenoxy)acetyl]amino]benzoic Acid
  参考文献：
  名称：

  苯并呋喃[3,2 - b ]喹啉-6（11 H）one及其衍生物的合成

  摘要：

  报道了一种新的高效合成苯并f'uro [3,2 - b ]喹啉-6（11 H）的一（3）的方法，该方法是用2-{[（（苯氧基）乙酰基]氨基}苯甲酸（6a）处理多磷酸。定义了3至6a转化的中间体，即2-（3-苯并呋喃基氨基）苯甲酸（7）。用于合成的改进方法6a中还描述的，将其用于制备类似物（图6b-N的）6a中。另外，苯并呋喃[3，2-]的11-烷氧基衍生物（8）和11-二烷基氨基衍生物（10和11）。b ]喹啉由3制备。

  DOI：

  10.1002/jhet.5570150826

文献信息

• Identification of Anthranilic Acid Derivatives as a Novel Class of Allosteric Inhibitors of Hepatitis C NS5B Polymerase
  作者：Thomas Nittoli、Kevin Curran、Shabana Insaf、Martin DiGrandi、Mark Orlowski、Rajiv Chopra、Atul Agarwal、Anita Y. M. Howe、Amar Prashad、M. Brawner Floyd、Bernard Johnson、Alan Sutherland、Karen Wheless、Boris Feld、John O'Connell、Tarek S. Mansour、Jonathan Bloom

  DOI：10.1021/jm061428x

  日期：2007.5.1

  A series of potent anthranilic acid-based inhibitors of the hepatitis C NS5B polymerase has been identified. The inhibitors bind to a site on NS5B between the thumb and palm regions adjacent to the active site as determined by X-ray crystallography of the enzyme-inhibitor complex. Guided by both molecular modeling and traditional SAR, the enzyme activity of the initial hit was improved by approximately

  已鉴定出一系列强效邻氨基苯甲酸丙型肝炎 NS5B 聚合酶抑制剂。通过酶抑制剂复合物的 X 射线晶体学测定，抑制剂与 NS5B 上拇指和手掌区域之间与活性位点相邻的位点结合。在分子建模和传统 SAR 的指导下，初始命中的酶活性提高了约 100 倍，产生了一系列有效且选择性的 NS5B 抑制剂，IC50 值低至 10 nM。这些化合物也是培养的 HUH7 细胞中 HCV 复制子的抑制剂。
• SUNDER S.; PEET N. P., J. HETEROCYCL. CHEM., 1978, 15, NO 8, 1379-1382
  作者：SUNDER S.、 PEET N. P.

  DOI：——

  日期：——
• COMBINATION TABLET WITH CHEWABLE OUTER LAYER
  申请人：Vitalis LLC

  公开号：US20170042821A1

  公开（公告）日：2017-02-16

  A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis.
• Combination Tablet With Chewable Outer Layer
  申请人：Vitalis LLC

  公开号：US20200046644A1

  公开（公告）日：2020-02-13

  A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis.
• US5741926A
  申请人：——

  公开号：US5741926A

  公开（公告）日：1998-04-21